T14	Exp 186 188	We
T15	Exp 203 218	the feasibility
T16	Exp 342 352	this study
T17	Exp 430 459	the new approved nomenclature
T18	Exp 522 546	the HIV-1-infected cells
T19	Exp 493 505	this article
T20	Exp 584 607	the NF-kappa B elements
T21	Exp 611 624	the HIV-1 LTR
T22	Exp 747 770	the NF-kappa B elements
T23	Exp 774 787	the HIV-1 LTR
T24	Exp 819 824	the 5
T25	Exp 888 923	the IFN-stimulated response element
T26	Exp 1071 1091	the human IFNA2 gene
T27	Exp 1011 1067	Insertion of this chimeric promoter (ISG15 LTR) upstream
T28	Exp 1161 1174	this promoter
T29	Exp 1286 1307	the retrovirus vector
T30	Exp 1435 1450	their abilities
T31	Exp 1805 1819	the U937 cells
T32	Exp 1884 1897	the IFNA gene
T33	Exp 1921 1925	that
T34	Exp 2000 2004	that
T35	Exp 1899 1912	These results
R2	Coref Anaphora:T30 Antecedent:T36
T1	Protein 67 70	Tat
T2	Protein 649 652	Tat
T3	Protein 944 947	Tat
T4	Protein 1081 1086	IFNA2
T5	Protein 1133 1136	Tat
T6	Protein 1197 1224	tumor necrosis factor alpha
T7	Protein 1402 1407	IFN A
T8	Protein 1409 1413	IFNA
T9	Protein 1462 1475	interleukin-2
T10	Protein 1525 1543	phytohemagglutinin
T11	Protein 1604 1608	IFNA
T12	Protein 1759 1763	IFNA
T13	Protein 1888 1892	IFNA
T36	Exp 1372 1378	clones
